|
|
|
|
|
|
|
|
Basic InformationMore Information"I Can't," Living with ADHDA Look at Attention Deficit Hyperactivity DisorderAdditional Information about ADHDADHD and Brain Stimulation ADHD and Stimulant Medications, A Matter of JudgementADHD OverviewADHD SymptomsADHD TreatmentsADHD, Medication and ExerciseAdolescents with ADHD and the Risk of Internet AddictionAdult ADHD and the HolidaysAdult ADHD, Some Additional ThoughtsAdults With ADHD at WorkAn Interview with Ari Tuckman, PsyD, MBA, on Adult ADHDAttention Deficit Hyperactivity DisorderChildren, ADHD and Stimulant MedicationChildren, Television, Video Games and Attention ProblemsChoosing Appropriate Toys for Children with ADHDDo I Have ADD?Intervention, ADHD, Addiction and Enabling and the Family CrucibleIt Is Me, Vinnie's Mom: Intervention, ADHD and the Family Crucible ContinuedOnline Resources for ADHDParenting, ADHD and Childhood Behavior ProblemsSelf Help for Adult ADHDThe ADHD e-BOOKThe Brain, Nutrition and ADHDThe Holidays with ADHD Children TestsLatest NewsQuestions and AnswersLinksBook ReviewsSelf-Help Groups |
| |
Antidepressants Don't Impact Stimulants' Efficacy in ADHD
Updated: Aug 16th 2011
TUESDAY, Aug. 16 (HealthDay News) -- In adults with attention deficit hyperactivity disorder (ADHD), concomitant use of antidepressants does not affect the safety or efficacy of osmotic release oral system methylphenidate (OROS-MPH), according to a study published online Aug. 5 in CNS Neuroscience & Therapeutics.
Joseph Biederman, M.D., from Massachusetts General Hospital in Boston, and colleagues examined whether the response to OROS-MPH was moderated by the concomitant use of antidepressants in adults with ADHD. A total of 223 patients with anxiety disorders and depression were analyzed, including 109 in the OROS-MPH group and 114 in the placebo group. Patients treated with a stable medication regimen of non-monoamine oxidase inhibitor antidepressants or benzodiazepines for at least three months were enrolled. Patients were required to have Hamilton-Depression and Hamilton-Anxiety scales below 15 (mild range) at the time they were enrolled.
The investigators found no association between concomitant antidepressant use at baseline and ADHD response, OROS-MPH dose, study completion rate, adverse effects, or worsening of anxiety or depression. There was nominally significant evidence of a lifetime history of mood or anxiety disorders being a moderator of ADHD symptoms. A potential moderator of dose at end point was a lifetime history of substance use disorder.
"We found few moderating effects in this large clinical trial of OROS-MPH in adults with ADHD, which supports the robustness of the clinical response to OROS-MPH in adult ADHD despite variable clinical pictures," the authors write.
All of the study authors disclosed financial relationships with the pharmaceutical and health care industry, including Ortho-McNeil Janssen Scientific Affairs, which provided financial support for the study.
Abstract
Full Text (subscription or payment may be required)
This article: Copyright © 2011 HealthDay. All rights reserved. |
| 
|
|
